Consensus statements on vaccination in patients with haemophilia—results from the italian haemophilia and vaccinations (Heva) project

HEVA Study Group, Elena Santagostino, Agostino Riva, Simone Cesaro, Susanna Esposito, Davide Matino, Renata Ilde Mazzucchelli, Angelo Claudio Molinari, Rosamaria Mura, Lucia Dora Notarangelo, Annarita Tagliaferri, Giovanni Di Minno, Mario Clerici

Research output: Contribution to journalArticle

Abstract

Vaccination against communicable diseases is crucial for disease prevention, but this practice poses challenges to healthcare professionals in patients with haemophilia. Poor knowledge of the vaccination requirements for these patients and safety concerns often result in vaccination delay or avoidance. In order to address this issue, a panel of 11 Italian haemophilia and immunization experts conducted a Delphi consensus process to identify the main concerns regarding the safe use of vaccines in patients with haemophilia. The consensus was based on a literature search of the available evidence, which was used by the experts to design 27 consensus statements. A group of clinicians then rated these statements using the 5�?point Likert-type scale (1 = strongly disagree; 5 = strongly agree). The main issues identified by the expert panel included vaccination schedule for haemophilic patients; protocol and optimal route of vaccine administration; vaccination of haemophilic patients with antibodies inhibiting coagulation factor VIII (inhibitors); and vaccination and risk of inhibitor development. This manuscript discusses these controversial areas in detail supported by the available literature evidence and provides evidence�? and consensus-based recommendations. Overall, participants agreed on most statements, except those addressing the potential role of vaccination in inhibitor formation. Participants agreed that patients with haemophilia should receive vaccinations according to the institutional schedule for individuals without bleeding disorders; however, vaccination of patients with haemophilia requires comprehensive planning, taking into account disease severity, type and route of vaccination, and bleeding risk. Data also suggest vaccination timing does not need to take into consideration when the patient received factor VIII replacement.

Original languageEnglish
Pages (from-to)656-667
JournalHaemophilia
Volume25
Issue number4
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Hemophilia A
Vaccination
Factor VIII
Appointments and Schedules
Vaccines
Hemorrhage
Patient Safety
Communicable Diseases
Immunization
Delivery of Health Care

Keywords

  • Bleeding disorder
  • Factor VIII inhibitor
  • Haemophilia
  • Immunization
  • Vaccination

ASJC Scopus subject areas

  • Hematology
  • Genetics(clinical)

Cite this

Consensus statements on vaccination in patients with haemophilia—results from the italian haemophilia and vaccinations (Heva) project. / HEVA Study Group ; Santagostino, Elena; Riva, Agostino; Cesaro, Simone; Esposito, Susanna; Matino, Davide; Mazzucchelli, Renata Ilde; Molinari, Angelo Claudio; Mura, Rosamaria; Notarangelo, Lucia Dora; Tagliaferri, Annarita; Di Minno, Giovanni; Clerici, Mario.

In: Haemophilia, Vol. 25, No. 4, 01.01.2019, p. 656-667.

Research output: Contribution to journalArticle

HEVA Study Group, Santagostino, E, Riva, A, Cesaro, S, Esposito, S, Matino, D, Mazzucchelli, RI, Molinari, AC, Mura, R, Notarangelo, LD, Tagliaferri, A, Di Minno, G & Clerici, M 2019, 'Consensus statements on vaccination in patients with haemophilia—results from the italian haemophilia and vaccinations (Heva) project', Haemophilia, vol. 25, no. 4, pp. 656-667. https://doi.org/10.1111/hae.13756
HEVA Study Group ; Santagostino, Elena ; Riva, Agostino ; Cesaro, Simone ; Esposito, Susanna ; Matino, Davide ; Mazzucchelli, Renata Ilde ; Molinari, Angelo Claudio ; Mura, Rosamaria ; Notarangelo, Lucia Dora ; Tagliaferri, Annarita ; Di Minno, Giovanni ; Clerici, Mario. / Consensus statements on vaccination in patients with haemophilia—results from the italian haemophilia and vaccinations (Heva) project. In: Haemophilia. 2019 ; Vol. 25, No. 4. pp. 656-667.
@article{dd16fb4d82ef4596b24d53ffda3e8533,
title = "Consensus statements on vaccination in patients with haemophilia—results from the italian haemophilia and vaccinations (Heva) project",
abstract = "Vaccination against communicable diseases is crucial for disease prevention, but this practice poses challenges to healthcare professionals in patients with haemophilia. Poor knowledge of the vaccination requirements for these patients and safety concerns often result in vaccination delay or avoidance. In order to address this issue, a panel of 11 Italian haemophilia and immunization experts conducted a Delphi consensus process to identify the main concerns regarding the safe use of vaccines in patients with haemophilia. The consensus was based on a literature search of the available evidence, which was used by the experts to design 27 consensus statements. A group of clinicians then rated these statements using the 5�?point Likert-type scale (1 = strongly disagree; 5 = strongly agree). The main issues identified by the expert panel included vaccination schedule for haemophilic patients; protocol and optimal route of vaccine administration; vaccination of haemophilic patients with antibodies inhibiting coagulation factor VIII (inhibitors); and vaccination and risk of inhibitor development. This manuscript discusses these controversial areas in detail supported by the available literature evidence and provides evidence�? and consensus-based recommendations. Overall, participants agreed on most statements, except those addressing the potential role of vaccination in inhibitor formation. Participants agreed that patients with haemophilia should receive vaccinations according to the institutional schedule for individuals without bleeding disorders; however, vaccination of patients with haemophilia requires comprehensive planning, taking into account disease severity, type and route of vaccination, and bleeding risk. Data also suggest vaccination timing does not need to take into consideration when the patient received factor VIII replacement.",
keywords = "Bleeding disorder, Factor VIII inhibitor, Haemophilia, Immunization, Vaccination",
author = "{HEVA Study Group} and Elena Santagostino and Agostino Riva and Simone Cesaro and Susanna Esposito and Davide Matino and Mazzucchelli, {Renata Ilde} and Molinari, {Angelo Claudio} and Rosamaria Mura and Notarangelo, {Lucia Dora} and Annarita Tagliaferri and {Di Minno}, Giovanni and Mario Clerici",
year = "2019",
month = "1",
day = "1",
doi = "10.1111/hae.13756",
language = "English",
volume = "25",
pages = "656--667",
journal = "Haemophilia",
issn = "1351-8216",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "4",

}

TY - JOUR

T1 - Consensus statements on vaccination in patients with haemophilia—results from the italian haemophilia and vaccinations (Heva) project

AU - HEVA Study Group

AU - Santagostino, Elena

AU - Riva, Agostino

AU - Cesaro, Simone

AU - Esposito, Susanna

AU - Matino, Davide

AU - Mazzucchelli, Renata Ilde

AU - Molinari, Angelo Claudio

AU - Mura, Rosamaria

AU - Notarangelo, Lucia Dora

AU - Tagliaferri, Annarita

AU - Di Minno, Giovanni

AU - Clerici, Mario

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Vaccination against communicable diseases is crucial for disease prevention, but this practice poses challenges to healthcare professionals in patients with haemophilia. Poor knowledge of the vaccination requirements for these patients and safety concerns often result in vaccination delay or avoidance. In order to address this issue, a panel of 11 Italian haemophilia and immunization experts conducted a Delphi consensus process to identify the main concerns regarding the safe use of vaccines in patients with haemophilia. The consensus was based on a literature search of the available evidence, which was used by the experts to design 27 consensus statements. A group of clinicians then rated these statements using the 5�?point Likert-type scale (1 = strongly disagree; 5 = strongly agree). The main issues identified by the expert panel included vaccination schedule for haemophilic patients; protocol and optimal route of vaccine administration; vaccination of haemophilic patients with antibodies inhibiting coagulation factor VIII (inhibitors); and vaccination and risk of inhibitor development. This manuscript discusses these controversial areas in detail supported by the available literature evidence and provides evidence�? and consensus-based recommendations. Overall, participants agreed on most statements, except those addressing the potential role of vaccination in inhibitor formation. Participants agreed that patients with haemophilia should receive vaccinations according to the institutional schedule for individuals without bleeding disorders; however, vaccination of patients with haemophilia requires comprehensive planning, taking into account disease severity, type and route of vaccination, and bleeding risk. Data also suggest vaccination timing does not need to take into consideration when the patient received factor VIII replacement.

AB - Vaccination against communicable diseases is crucial for disease prevention, but this practice poses challenges to healthcare professionals in patients with haemophilia. Poor knowledge of the vaccination requirements for these patients and safety concerns often result in vaccination delay or avoidance. In order to address this issue, a panel of 11 Italian haemophilia and immunization experts conducted a Delphi consensus process to identify the main concerns regarding the safe use of vaccines in patients with haemophilia. The consensus was based on a literature search of the available evidence, which was used by the experts to design 27 consensus statements. A group of clinicians then rated these statements using the 5�?point Likert-type scale (1 = strongly disagree; 5 = strongly agree). The main issues identified by the expert panel included vaccination schedule for haemophilic patients; protocol and optimal route of vaccine administration; vaccination of haemophilic patients with antibodies inhibiting coagulation factor VIII (inhibitors); and vaccination and risk of inhibitor development. This manuscript discusses these controversial areas in detail supported by the available literature evidence and provides evidence�? and consensus-based recommendations. Overall, participants agreed on most statements, except those addressing the potential role of vaccination in inhibitor formation. Participants agreed that patients with haemophilia should receive vaccinations according to the institutional schedule for individuals without bleeding disorders; however, vaccination of patients with haemophilia requires comprehensive planning, taking into account disease severity, type and route of vaccination, and bleeding risk. Data also suggest vaccination timing does not need to take into consideration when the patient received factor VIII replacement.

KW - Bleeding disorder

KW - Factor VIII inhibitor

KW - Haemophilia

KW - Immunization

KW - Vaccination

UR - http://www.scopus.com/inward/record.url?scp=85065794835&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065794835&partnerID=8YFLogxK

U2 - 10.1111/hae.13756

DO - 10.1111/hae.13756

M3 - Article

VL - 25

SP - 656

EP - 667

JO - Haemophilia

JF - Haemophilia

SN - 1351-8216

IS - 4

ER -